170230-17-8

Upstream product

• 619-10-3 5-nitro-2-chlorophenol 
• 28443-52-9 2-chloro-5-acetylamino phenol 
• 1349821-33-5 N-[4-chloro-3-(2-dimethylaminoethoxy)phenyl]acetamide 
• 345893-27-8 tert-butyl (4-chloro-3-hydroxyphenyl)carbamate 
• 30533-51-8 dimethylaminoethyl chloride (hydrochloride) 

Downstream Products

• 345892-67-3 N-[4-Chloro-3-(2-dimethylamino-ethoxy)-phenyl]-3,4-dimethoxy-benzenesulfonamide 
• 345892-68-4 4,5-Dibromo-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-2-thiophenesulfonamide 
• 345892-71-9 SB 611812 
• 345892-72-0 2-Bromo-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-4,5-dimethoxy-benzenesulfonamide 
• 1428555-04-7 C₁₈H₂₀ClF₃N₂O 
• 1428555-02-5 C₁₇H₂₀BrClN₂O 
• 1428555-01-4 C₁₇H₂₁ClN₂O 
• 758711-95-4 1-(4-Chloro-3-(2-dimethylamino-ethoxy)-phenyl)-3-(2-methyl-quinolin-4-yl)-urea 
• 345892-69-5 3,4-Dibromo-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide 

Relevant academic research and scientific papers

POTENT AND SELCTIVE COMPOUNDS AS SEROTONIN 1B RECEPTOR MODULATORS

The present invention relates to new compounds of formula (I): as modulators of serotonin receptor 1B (5-HTR1B) also known as 5-hydroxytryptamine receptor 1B (5-HT1B). The compounds are of potential utility in the treatment of diseases and conditions mediated by serotonin receptor type 1B (5-HTR1B), such as cancer, including blood cancer and solid tumors, respiratory diseases and hepatic disorders.

4(1H)-Quinolones Having Antimalarial Activity With Reduced Chemical Resistance

Provided are 4(1H)-quinolone derivatives effective in inhibiting or eliminating the viability of at least one of the stages in the life-cycle of the malarial parasite, and to show a reduced propensity to induce resistance to the compound by the target parasite. In particular, the compounds can be derivatives of phenoxyethoxy-quinolones, and including, but not only, 7-(2-phenoxyethoxy)quinolin derivatives. These compounds may be administered by themselves, with at least one other derivative compound, or with other antimalarial compounds, to an animal or human subject. The therapeutic compositions can be and formulated to reduce the extent of a Plasmodium infection in the recipient subject, or to reduce the likelihood of the onset or establishment of a Plasmodium infection if administered prior to the parasite contacting the subject. The therapeutic compositions can be formulated to provide an effective single dose amount of an antimalarial compound or multiple doses for administering over a period of time.

Synthesis, antimalarial activity, and structure-activity relationship of 7-(2-Phenoxyethoxy)-4(1H)-quinolones

ICI 56,780 (5) displayed causal prophylactic and blood schizonticidal activity (ED50 = 0.05 mg/kg) in rodent malaria models but produced rapid acquisition of parasitological resistance in P. berghei infected mice. Herein we describe the synthesis of analogues of 5 with EC50 as low as 0.15 nM against multidrug resistant P. falciparum. Optimal activity with low cross-resistance indexes (RI) to atovaquone was achieved by introducing ortho-substituted aryl moieties at the 3-position of the 7-(2-phenoxyethoxy)- 4(1H)-quinolone core. (Figure presented

Urotensin-II receptor antagonists

P51084 The present invention relates to sulfonamides, pharmaceutical compositions containing them, and their use as antagonists of urotensin II.